Prognostic value of high-sensitivity cardiac troponin I in
heart failure patients with mid-range and reduced ejection
fraction

J 2021

Prognostic value of high-sensitivity cardiac troponin I in heart failure patients with mid-range and reduced ejection fraction

LOKAJ, Petr; Jindřich ŠPINAR; Lenka ŠPINAROVÁ; Filip MALEK; Ondřej LUDKA et al.

Základní údaje

Originální název

Prognostic value of high-sensitivity cardiac troponin I in heart failure patients with mid-range and reduced ejection fraction

Autoři

Vydání

Plos one, San Francisco, Public Library Science, 2021, 1932-6203

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10700 1.7 Other natural sciences

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.752

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/21:00122391

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

high-sensitivity cardiac troponin I; heart failure patients; ejection fraction

Štítky

14110115, 14110211, 14110518, 14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 21. 9. 2021 09:12, Mgr. Tereza Miškechová

Anotace

V originále

Background The identification of high-risk heart failure (HF) patients makes it possible to intensify their treatment. Our aim was to determine the prognostic value of a newly developed, high-sensitivity troponin I assay (Atellica(R), Siemens Healthcare Diagnostics) for patients with HF with reduced ejection fraction (HFrEF; LVEF < 40%) and HF with mid-range EF (HFmrEF) (LVEF 40%-49%). Methods and results A total of 520 patients with HFrEF and HFmrEF were enrolled in this study. Two-year all-cause mortality, heart transplantation, and/or left ventricular assist device implantation were defined as the primary endpoints (EP). A logistic regression analysis was used for the identification of predictors and development of multivariable models. The EP occurred in 14% of the patients, and these patients had higher NT-proBNP (1,950 vs. 518 ng/l; p < 0.001) and hs-cTnI (34 vs. 17 ng/l, p < 0.001) levels. C-statistics demonstrated that the optimal cut-off value for the hs-cTnI level was 17 ng/l (AUC 0.658, p < 0.001). Described by the AUC, the discriminatory power of the multivariable model (NYHA > II, NT-proBNP, hs-cTnI and urea) was 0.823 (p < 0.001). Including heart failure hospitalization as the component of the combined secondary endpoint leads to a diminished predictive power of increased hs-cTnI. Conclusion hs-cTnI levels >= 17 ng/l represent an independent increased risk of an adverse prognosis for patients with HFrEF and HFmrEF. Determining a patient's hs-cTnI level adds prognostic value to NT-proBNP and clinical parameters.

Citovat

LOKAJ, Petr; Jindřich ŠPINAR; Lenka ŠPINAROVÁ; Filip MALEK; Ondřej LUDKA; Jan KREJČÍ; Petr OSTADAL; Dagmar VONDRAKOVA; Karel LÁBR; Monika ŠPINAROVÁ; Monika PÁVKOVÁ GOLDBERGOVÁ; Marie MIKLÍKOVÁ; Kateřina HELÁNOVÁ; Ilona PARENICOVA; Vladimír JAKUBO; Klára BENEŠOVÁ; Roman MIKLIK; Jiří JARKOVSKÝ; Tomáš ONDRÚŠ a Jiří PAŘENICA. Prognostic value of high-sensitivity cardiac troponin I in heart failure patients with mid-range and reduced ejection fraction. Plos one. San Francisco: Public Library Science, 2021, roč. 16, č. 7, s. 1-14. ISSN 1932-6203. Dostupné z: https://doi.org/10.1371/journal.pone.0255271.

@article{1793185,
   author = {Lokaj, Petr and Špinar, Jindřich and Špinarová, Lenka and Malek, Filip and Ludka, Ondřej and Krejčí, Jan and Ostadal, Petr and Vondrakova, Dagmar and Lábr, Karel and Špinarová, Monika and Pávková Goldbergová, Monika and Miklíková, Marie and Helánová, Kateřina and Parenicova, Ilona and Jakubo, Vladimír and Benešová, Klára and Miklik, Roman and Jarkovský, Jiří and Ondrúš, Tomáš and Pařenica, Jiří},
   article_location = {San Francisco},
   article_number = {7},
   doi = {https://doi.org/10.1371/journal.pone.0255271},
   keywords = {high-sensitivity cardiac troponin I; heart failure patients; ejection fraction},
   language = {eng},
   issn = {1932-6203},
   journal = {Plos one},
   title = {Prognostic value of high-sensitivity cardiac troponin I in heart failure patients with mid-range and reduced ejection fraction},
   url = {https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0255271},
   volume = {16},
   year = {2021}
}

TY  - JOUR
ID  - 1793185
AU  - Lokaj, Petr - Špinar, Jindřich - Špinarová, Lenka - Malek, Filip - Ludka, Ondřej - Krejčí, Jan - Ostadal, Petr - Vondrakova, Dagmar - Lábr, Karel - Špinarová, Monika - Pávková Goldbergová, Monika - Miklíková, Marie - Helánová, Kateřina - Parenicova, Ilona - Jakubo, Vladimír - Benešová, Klára - Miklik, Roman - Jarkovský, Jiří - Ondrúš, Tomáš - Pařenica, Jiří
PY  - 2021
TI  - Prognostic value of high-sensitivity cardiac troponin I in heart failure patients with mid-range and reduced ejection fraction
JF  - Plos one
VL  - 16
IS  - 7
SP  - 1-14
EP  - 1-14
PB  - Public Library Science
SN  - 19326203
KW  - high-sensitivity cardiac troponin I
KW  - heart failure patients
KW  - ejection fraction
UR  - https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0255271
N2  - Background The identification of high-risk heart failure (HF) patients makes it possible to intensify their treatment. Our aim was to determine the prognostic value of a newly developed, high-sensitivity troponin I assay (Atellica(R), Siemens Healthcare Diagnostics) for patients with HF with reduced ejection fraction (HFrEF; LVEF < 40%) and HF with mid-range EF (HFmrEF) (LVEF 40%-49%). Methods and results A total of 520 patients with HFrEF and HFmrEF were enrolled in this study. Two-year all-cause mortality, heart transplantation, and/or left ventricular assist device implantation were defined as the primary endpoints (EP). A logistic regression analysis was used for the identification of predictors and development of multivariable models. The EP occurred in 14% of the patients, and these patients had higher NT-proBNP (1,950 vs. 518 ng/l; p < 0.001) and hs-cTnI (34 vs. 17 ng/l, p < 0.001) levels. C-statistics demonstrated that the optimal cut-off value for the hs-cTnI level was 17 ng/l (AUC 0.658, p < 0.001). Described by the AUC, the discriminatory power of the multivariable model (NYHA > II, NT-proBNP, hs-cTnI and urea) was 0.823 (p < 0.001). Including heart failure hospitalization as the component of the combined secondary endpoint leads to a diminished predictive power of increased hs-cTnI. Conclusion hs-cTnI levels >= 17 ng/l represent an independent increased risk of an adverse prognosis for patients with HFrEF and HFmrEF. Determining a patient's hs-cTnI level adds prognostic value to NT-proBNP and clinical parameters.
ER  -

LOKAJ, Petr; Jindřich ŠPINAR; Lenka ŠPINAROVÁ; Filip MALEK; Ondřej LUDKA; Jan KREJČÍ; Petr OSTADAL; Dagmar VONDRAKOVA; Karel LÁBR; Monika ŠPINAROVÁ; Monika PÁVKOVÁ GOLDBERGOVÁ; Marie MIKLÍKOVÁ; Kateřina HELÁNOVÁ; Ilona PARENICOVA; Vladimír JAKUBO; Klára BENEŠOVÁ; Roman MIKLIK; Jiří JARKOVSKÝ; Tomáš ONDRÚŠ a Jiří PAŘENICA. Prognostic value of high-sensitivity cardiac troponin I in heart failure patients with mid-range and reduced ejection fraction. \textit{Plos one}. San Francisco: Public Library Science, 2021, roč.~16, č.~7, s.~1-14. ISSN~1932-6203. Dostupné z: https://doi.org/10.1371/journal.pone.0255271.

Přehled o publikaci